ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute discusses the EnzaMet and EnzaRad study designs, eligibility requirements, and endpoints (Abstracts TPS5077 and TPS5078).

Prostate Cancer

Nicholas David James, MD, PhD, and Celestia S. Higano, MD

Nicholas David James, MD, PhD, and Celestia S. Higano, MD, on Results From the STAMPEDE Trial on Hormone-Naive Prostate Cancer

Celestia S. Higano, MD, of the University of Washington, and Nicholas David James, MD, PhD, of Warwick Medical School, discuss data showing improvements in survival from adding docetaxel in men starting long-term hormone therapy for the first time (Abstract 5001).

Colorectal Cancer

Dung T. Le, MD, and Axel Grothey, MD

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).

Bladder Cancer

Prostate Cancer

Derek Raghavan, MD, PhD

Derek Raghavan, MD, PhD: Roundup of Clinical Trial Results on Genitourinary Cancers

Derek Raghavan, MD, PhD, of the Levine Cancer Institute, gives his insights into key genitourinary cancer clinical trials presented at the 2015 ASCO Annual Meeting and his thoughts on where the research is headed.

Lung Cancer

Carolyn Jean Presley, MD, and James L. Mulshine, MD

Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

James L. Mulshine, MD, of Rush University Medical Center, and Carolyn Jean Presley, MD, of Yale Cancer Center/Yale School of Medicine, discuss the burden on patients and the Medicare system as new lung cancer CT guidelines are put into effect and treatment of early-stage NSCLC increases (Abstract 7533).

Jul

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Christopher Sweeney, MBBS, Summarizes the ENZAMET and ENZARAD Trials for Prostate Cancer

Nicholas David James, MD, PhD, and Celestia S. Higano, MD, on Results From the STAMPEDE Trial on Hormone-Naive Prostate Cancer

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Derek Raghavan, MD, PhD: Roundup of Clinical Trial Results on Genitourinary Cancers

Carolyn Jean Presley, MD, and James L. Mulshine, MD, on New Lung Cancer CT Screening Guidelines and Treatment Burden

Preclinical Research Shows Interferon May Attenuate Neutrophil Response to Cancer Immunotherapy

AI-Powered Tumor Microenvironment Analysis May Predict Immunotherapy Response in Patients With Rare Cancers

Performance of Lung Cancer Risk Prediction Models Across Racial and Ethnic Groups in the United States

Study Uncovers How Obesity Influences Molecular Pathways in Breast Cancer Progression

Study Clarifies HPV-Related Cancer Risk in Immunosuppressed Populations